US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immix Biopharma, Inc.

1.87

+0.12006.86%

Post-market: 1.870.00000.00%16:24 EDT

Volume:68.22K

Turnover:122.51K

Market Cap:51.84M

PE:-2.45

High:1.88

Open:1.70

Low:1.70

Close:1.75

Loading ...

Overview Company News Filings

Immix Biopharma’s Nxc-201 Nexicart-2 Clinical Trial Data Selected for Oral Presentation at Asco 2025

THOMSON REUTERS

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

Immix Biopharma Inc expected to post a loss of 23 cents a share - Earnings Preview

Immix Biopharma Says FDA Grants Regenerative Medicine Advanced Therapy Designation to NXC-201 Cell Therapy

MT Newswires Live

BRIEF-Immix Biopharma Receives FDA RMAT Designation For NXC-201

Immix Biopharma receives FDA RMAT designation for NCX-201 in r/r AL Amyloidosis

Immix Biopharma Inc: Enrollment in Nexicart-2 Study Accelerating; Next Update Planned for H1 2025

THOMSON REUTERS

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Nxc-201, Sterically-Optimized CAR-T for Relapsed/Refractory Al Amyloidosis

THOMSON REUTERS

Several Insiders Invested In Immix Biopharma Flagging Positive News

Simply Wall St.

BRIEF-Immix Biopharma Accelerates Enrollment In U.S. AL Amyloidosis Trial Of NXC-201 CAR-T

Immix Biopharma Says Patients Dosed in AL Amyloidosis Trial Safety Run-in Successfully Complete Safety Evaluation

MT Newswires Live

Immix Biopharma accelerates enrollment in U.S. AL amyloidosis trial of NXC-201

Immix Biopharma Accelerates Enrollment in U.S. Al Amyloidosis Trial of Nxc-201 CAR-T

THOMSON REUTERS

Immix Biopharma Inc: on Track for Next Program Update in Q1 2025

THOMSON REUTERS

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

Immix Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Analysts Offer Insights on Healthcare Companies: Acumen Pharmaceuticals (ABOS) and Immix Biopharma, Inc. (IMMX)

BRIEF-Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients In Nexicart-2 U.S. Trial

Immix Biopharma Reports Initial Data from US Trial of NXC-201 CAR-T Therapy for AL Amyloidosis

MT Newswires Live

Immix Biopharma announces data from four patients in NEXICART-2 U.S. trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMMX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMMX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMMX\",,,,,undefined,":{"symbol":"IMMX","market":"US","secType":"STK","nameCN":"Immix Biopharma, Inc.","latestPrice":1.87,"timestamp":1745611200000,"preClose":1.75,"halted":0,"volume":68224,"hourTrading":{"tag":"盘后","latestPrice":1.87,"preClose":1.87,"latestTime":"16:24 EDT","volume":48,"amount":91.2,"timestamp":1745612647228},"delay":0,"floatShares":17986724,"shares":27722108,"eps":-0.764111,"marketStatus":"Market Closed","change":0.12,"latestTime":"04-25 16:00:00 EDT","open":1.7042,"high":1.8842,"low":1.7,"amount":122505.6046,"amplitude":0.105257,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.764111,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1639630800000,"exchange":"NASDAQ","adjPreClose":1.75,"postHourTrading":{"tag":"盘后","latestPrice":1.87,"preClose":1.87,"latestTime":"16:24 EDT","volume":48,"amount":91.2,"timestamp":1745612647228},"volumeRatio":2.875204409748339,"impliedVol":1.0111,"impliedVolPercentile":0.828},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMMX\",,,,,undefined,":{"symbol":"IMMX","floatShares":17986724,"roa":"-66.11%","roe":"-147.33%","lyrEps":-0.764111,"volumeRatio":2.875204409748339,"shares":27722108,"dividePrice":0,"high":1.8842,"amplitude":0.105257,"preClose":1.75,"low":1.7,"week52Low":1.26,"pbRate":"3.91","week52High":2.71,"institutionHeld":0,"latestPrice":1.87,"eps":-0.764111,"divideRate":0,"volume":68224,"delay":0,"ttmEps":-0.764111,"open":1.7042,"prevYearClose":2.2,"prevWeekClose":1.64,"prevMonthClose":1.68,"prevQuarterClose":1.68,"fiveDayClose":1.64,"twentyDayClose":1.71,"sixtyDayClose":2.06},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMMX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529682665","title":"Immix Biopharma’s Nxc-201 Nexicart-2 Clinical Trial Data Selected for Oral Presentation at Asco 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529682665","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529682665?lang=en_us&edition=fundamental","pubTime":"2025-04-23 22:04","pubTimestamp":1745417040,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA1C5C4Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2529680520","title":"Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529680520","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529680520?lang=en_us&edition=fundamental","pubTime":"2025-04-23 22:04","pubTimestamp":1745417040,"startTime":"0","endTime":"0","summary":"— Oral presentation Tuesday, June 3, 2025 in Chicago —。“Safety and efficacy data from NEXICART-2, the first US trial of CAR-T in R/R light chain  amyloidosis, NXC-201”。Session Name: 652. Oral Abstract Session – Hematologic Malignancies—Plasma Cell Dyscrasia. About AL AmyloidosisAL amyloidosis is caused by abnormal plasma cells in the bone marrow, which produce misfolded amyloid proteins that build-up in the heart, kidney, liver, and other organs. This build-up causes progressive and widespread organ damage, including heart and renal failure, leading to high mortality rates.The Amyloidosis market was $3.6 billion in 2017, and is expected to reach $6 billion in 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immix-biopharma-nxc-201-nexicart-140400135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4230","BK4139","BK4022","CAR","NXC","ODD","AL","IE0034390439.USD","IMMX","IE00B19Z6F94.USD","BK4104","BK4572","BK4183"],"gpt_icon":0},{"id":"2522880318","title":"Immix Biopharma Inc  expected to post a loss of 23 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2522880318","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522880318?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:15","pubTimestamp":1742933707,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc  expected to post a loss of23cents a share - Earnings Preview Immix Biopharma Inc IMMX.OQ IMMX.O is expected to report resultson May 7 (estimated) for the period ending March 31 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL5N3Q81XS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2510869097","title":"Immix Biopharma Says FDA Grants Regenerative Medicine Advanced Therapy Designation to NXC-201 Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2510869097","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510869097?lang=en_us&edition=fundamental","pubTime":"2025-02-10 23:36","pubTimestamp":1739201762,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) said Monday that the US Food and Drug Administration has granted regenerative medicine advanced therapy designation to NXC-201 as a potential treatment for relapsed/refractory A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B7SZL793.SGD","BK6088","IE00B19Z4B17.USD","BK4157","NXC","BK4139","BK6522","IMMX","AEIS","IE0031619046.USD","IE00B66KJ199.SGD","BLZ.SI"],"gpt_icon":0},{"id":"2510866728","title":"BRIEF-Immix Biopharma Receives FDA RMAT Designation For NXC-201","url":"https://stock-news.laohu8.com/highlight/detail?id=2510866728","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510866728?lang=en_us&edition=fundamental","pubTime":"2025-02-10 23:15","pubTimestamp":1739200519,"startTime":"0","endTime":"0","summary":"BRIEF-Immix Biopharma Receives FDA RMAT Designation For NXC-201Feb 10 (Reuters) - Immix Biopharma Inc IMMX.O:IMMIX BIOPHARMA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nFWN3P10W5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2510865617","title":"Immix Biopharma receives FDA RMAT designation for NCX-201 in r/r AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2510865617","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510865617?lang=en_us&edition=fundamental","pubTime":"2025-02-10 22:40","pubTimestamp":1739198437,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) announced that the U.S. FDA has granted RMAT designation to sterically-optimized CAR-T NXC-201 for the treatment of relapsed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-receives-fda-rmat-designation-for-ncx-201-in-r-r-al-amyloidosis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-receives-fda-rmat-designation-for-ncx-201-in-r-r-al-amyloidosis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4022","CAR","IE00B19Z6F94.USD","BK4104","BK4572","IE0034390439.USD","IMMX","BK4230","BK4139","AL"],"gpt_icon":0},{"id":"2510863390","title":"Immix Biopharma Inc: Enrollment in Nexicart-2 Study Accelerating; Next Update Planned for H1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2510863390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510863390?lang=en_us&edition=fundamental","pubTime":"2025-02-10 22:35","pubTimestamp":1739198110,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nFWN3P10W5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2510863318","title":"Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Nxc-201, Sterically-Optimized CAR-T for Relapsed/Refractory Al Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2510863318","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510863318?lang=en_us&edition=fundamental","pubTime":"2025-02-10 22:35","pubTimestamp":1739198110,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nFWN3P10W5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2509285130","title":"Several Insiders Invested In Immix Biopharma Flagging Positive News","url":"https://stock-news.laohu8.com/highlight/detail?id=2509285130","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509285130?lang=en_us&edition=fundamental","pubTime":"2025-02-05 21:17","pubTimestamp":1738761471,"startTime":"0","endTime":"0","summary":"Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Immix Biopharma, Inc. , that sends out a positive message to the company's shareholders.While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.The Last 12 Months Of Insider Transactions At Immix Biopharma. Insiders At Immix Biopharma Have Bought Stock Recently. It is good to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Given that insiders also own a fair bit of I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/several-insiders-invested-immix-biopharma-131751292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2501578900","title":"BRIEF-Immix Biopharma Accelerates Enrollment In U.S. AL Amyloidosis Trial Of NXC-201 CAR-T","url":"https://stock-news.laohu8.com/highlight/detail?id=2501578900","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501578900?lang=en_us&edition=fundamental","pubTime":"2025-01-08 00:08","pubTimestamp":1736266092,"startTime":"0","endTime":"0","summary":"Jan 7 (Reuters) - Immix Biopharma Inc   :   * IMMIX BIOPHARMA ACCELERATES ENROLLMENT IN U.S. AL AMYLOIDOSIS TRIAL OF NXC-201 CAR-T   * IMMIX BIOPHARMA INC: ON TRACK FOR NEXT PROGRAM UPDATE IN Q1 2025Source text:    Further company coverage:    (((( Reuters.Briefs@thomsonreuters.com ;));))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z6F94.USD","BK4104","IMMX","AL","IE0034390439.USD","BK4572","NXC","CAR","BK4139"],"gpt_icon":0},{"id":"2501828789","title":"Immix Biopharma Says Patients Dosed in AL Amyloidosis Trial Safety Run-in Successfully Complete Safety Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2501828789","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501828789?lang=en_us&edition=fundamental","pubTime":"2025-01-07 23:56","pubTimestamp":1736265375,"startTime":"0","endTime":"0","summary":"Immix Biopharma  said Tuesday six patients dosed in a phase 1b safety run-in segment of a trial of its experimental NXC-201 treatment of relapsed or refractory AL Amyloidosis successfully completed the trial's safety evaluation.The safety run-in segment dosed three patients at 150 million CAR-T cells and three patients at 450 million CAR-T cells.Immix said enrollment can now advance across US study sites at a dose of 450 million CAR-T cells.AL Amyloidosis is a life-threatening disorder of plasma cells in the bone marrow.Price: 2.29, Change: -0.01, Percent Change: -0.43","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B19Z6F94.USD","BK4230","CAR","BK4139","IMMX","AL","BK4572","IE0034390439.USD","BK4104","BK4022"],"gpt_icon":0},{"id":"2501778894","title":"Immix Biopharma accelerates enrollment in U.S. AL amyloidosis trial of NXC-201","url":"https://stock-news.laohu8.com/highlight/detail?id=2501778894","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501778894?lang=en_us&edition=fundamental","pubTime":"2025-01-07 22:41","pubTimestamp":1736260863,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) announced completion of the six-patient Phase 1b safety run-in segment in the U.S. NEXICART-2 study of NXC-201, an investiga...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-accelerates-enrollment-in-u-s-al-amyloidosis-trial-of-nxc-201?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-accelerates-enrollment-in-u-s-al-amyloidosis-trial-of-nxc-201?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0034390439.USD","BK4139","IMMX","NXC","AL","IE00B19Z6F94.USD","BK4104","BK4572"],"gpt_icon":0},{"id":"2501207086","title":"Immix Biopharma Accelerates Enrollment in U.S. Al Amyloidosis Trial of Nxc-201 CAR-T","url":"https://stock-news.laohu8.com/highlight/detail?id=2501207086","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501207086?lang=en_us&edition=fundamental","pubTime":"2025-01-07 22:34","pubTimestamp":1736260463,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nFWN3O3145:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2501089207","title":"Immix Biopharma Inc: on Track for Next Program Update in Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501089207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501089207?lang=en_us&edition=fundamental","pubTime":"2025-01-07 22:34","pubTimestamp":1736260463,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nFWN3O3145:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2501444200","title":"Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T","url":"https://stock-news.laohu8.com/highlight/detail?id=2501444200","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501444200?lang=en_us&edition=fundamental","pubTime":"2025-01-07 22:34","pubTimestamp":1736260440,"startTime":"0","endTime":"0","summary":"Successfully dosed 6 patients in safety run-in segment, now accelerating enrollment. Positive data from first four patients announced December 2024. NXC-201 is the only one-time CAR-T therapy in development for AL Amyloidosis. NEXICART-2 is an open-label study designed to evaluate NXC-201 in patients with R/R AL Amyloidosis. The study has two segments: a six-patient “safety run-in” segment and a 34-patient dose expansion segment. The Phase 1b “safety run-in” segment dosed three patients at 150 million CAR-T cells and three patients at 450 million CAR-T cells . All six patients successfully completed a post-dosing safety evaluation, and enrollment can now proceed across U.S. study sites at 450 million CAR-T cells.NXC-201 is the only CAR-T therapy currently in development in AL Amyloidosis, mentioned in a review article entitled “Systemic Light Chain Amyloidosis” published in June, 2024 New England Journal of Medicine .About NXC-201 NXC-201 is a sterically-optimized BCMA-targeted chimeri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immix-biopharma-accelerates-enrollment-u-143400342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMMX","CRS","BK4022","ODD","BK4572","LU2065731478.USD","IE00B7SZL793.SGD","BK4139","BK4006","BK4230","IE0034390439.USD","BK4183","IE00B19Z4B17.USD","IE00B19Z6F94.USD","NXC","CAR","BK4104","IE00B66KJ199.SGD","AL","IE0031619046.USD"],"gpt_icon":0},{"id":"2501782280","title":"Immix Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2501782280","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501782280?lang=en_us&edition=fundamental","pubTime":"2025-01-06 19:46","pubTimestamp":1736163960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2025 06:46 ET (11:46 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2501287201","title":"Analysts Offer Insights on Healthcare Companies: Acumen Pharmaceuticals (ABOS) and Immix Biopharma, Inc. (IMMX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2501287201","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501287201?lang=en_us&edition=fundamental","pubTime":"2025-01-06 19:30","pubTimestamp":1736163008,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Acumen Pharmaceuticals (ABOS – Research Report) and ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-acumen-pharmaceuticals-abos-and-immix-biopharma-inc-immx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-acumen-pharmaceuticals-abos-and-immix-biopharma-inc-immx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","HCSG","BK4137","ABOS","IMMX"],"gpt_icon":0},{"id":"2492102381","title":"BRIEF-Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients In Nexicart-2 U.S. Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2492102381","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492102381?lang=en_us&edition=fundamental","pubTime":"2024-12-20 02:04","pubTimestamp":1734631447,"startTime":"0","endTime":"0","summary":"Dec 19 (Reuters) - Immix Biopharma Inc   :   * IMMIX BIOPHARMA ANNOUNCES POSITIVE U.S. CLINICAL DATA FROM FIRST FOUR PATIENTS IN NEXICART-2 U.S. TRIAL OF STERICALLY-OPTIMIZED CAR-T NXC-201 IN RELAPSED","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034390439.USD","BK4572","IMMX","AL","IE00B19Z6F94.USD","BK4139","BK4104"],"gpt_icon":0},{"id":"2492105706","title":"Immix Biopharma Reports Initial Data from US Trial of NXC-201 CAR-T Therapy for AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2492105706","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492105706?lang=en_us&edition=fundamental","pubTime":"2024-12-20 00:38","pubTimestamp":1734626328,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) on Thursday reported initial clinical data from the first four patients in its ongoing trial of NXC-201 CAR-T cell therapy for relapsed/refractory AL Amyloidosis.All four patien","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4022","BK4572","CAR","NXC","IE00B19Z6F94.USD","BK4104","IMMX","IE0034390439.USD","BK4230","AL","BK4139"],"gpt_icon":0},{"id":"2492317484","title":"Immix Biopharma announces data from four patients in NEXICART-2 U.S. trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2492317484","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492317484?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:40","pubTimestamp":1734619232,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) announced initial clinical data from the first four patients in the ongoing NEXICART-2U.S. study of sterically-optimized BCM...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-announces-data-from-four-patients-in-nexicart-2-u-s-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-announces-data-from-four-patients-in-nexicart-2-u-s-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMMX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMMX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-24","symbol":"IMMX","fiscalQuarterEnding":"2024/12","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":-0.16},{"market":"US","date":"2024-11-12","symbol":"IMMX","fiscalQuarterEnding":"2024/09","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":-0.24},{"market":"US","date":"2024-08-12","symbol":"IMMX","fiscalQuarterEnding":"2024/06","expectedEps":-0.21,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723435200000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2024-05-09","symbol":"IMMX","fiscalQuarterEnding":"2024/03","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2024-03-29","symbol":"IMMX","fiscalQuarterEnding":"2023/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711684800000,"reportTimeType":"post","actualEps":-0.24}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMMX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IMMX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1719892800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IMMX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IMMX","date":"2025-04-24","current":-2.193309,"percent":0.631579,"low":-37.240428,"twenty":-5.45552,"median":-2.764482,"eighty":-1.18984,"high":-0.384227,"avg":-4.441151,"sd":5.712256,"marketCap":47404804},"quantilePoints":[{"date":"2021-12-17","current":-22.068402,"twenty":-20.976016,"median":-17.642249,"eighty":-15.03674,"marketCap":52834756},{"date":"2021-12-23","current":-16.275446,"twenty":-19.828459,"median":-17.958163,"eighty":-15.532222,"marketCap":38965632},{"date":"2021-12-31","current":-19.640878,"twenty":-19.806391,"median":-18.096089,"eighty":-16.937498,"marketCap":47022932},{"date":"2022-01-07","current":-29.461317,"twenty":-29.957856,"median":-19.420194,"eighty":-17.952645,"marketCap":70534399},{"date":"2022-01-14","current":-32.219867,"twenty":-32.197799,"median":-20.247759,"eighty":-17.985748,"marketCap":77138743},{"date":"2022-01-21","current":-24.882123,"twenty":-32.142628,"median":-24.882123,"eighty":-18.007816,"marketCap":59571187},{"date":"2022-01-28","current":-21.461521,"twenty":-32.021251,"median":-22.399428,"eighty":-18.140226,"marketCap":51381800},{"date":"2022-02-04","current":-24.109729,"twenty":-31.756431,"median":-22.399428,"eighty":-18.493321,"marketCap":57721970},{"date":"2022-02-11","current":-23.282164,"twenty":-31.039208,"median":-23.30975,"eighty":-19.276749,"marketCap":55740667},{"date":"2022-02-18","current":-19.75122,"twenty":-30.222677,"median":-22.399428,"eighty":-19.59674,"marketCap":47287106},{"date":"2022-02-25","current":-17.654721,"twenty":-29.957856,"median":-22.123573,"eighty":-18.096089,"marketCap":42267804},{"date":"2022-03-04","current":-11.641082,"twenty":-29.902685,"median":-21.875304,"eighty":-17.875406,"marketCap":27870333},{"date":"2022-03-11","current":-10.261807,"twenty":-29.461317,"median":-21.461521,"eighty":-16.440959,"marketCap":24568161},{"date":"2022-03-18","current":-13.296212,"twenty":-27.199305,"median":-20.771884,"eighty":-15.03674,"marketCap":31832940},{"date":"2022-03-25","current":-11.751424,"twenty":-26.592424,"median":-19.75122,"eighty":-13.241041,"marketCap":28134507},{"date":"2022-04-01","current":-1.409519,"twenty":-26.482082,"median":-19.392608,"eighty":-11.751424,"marketCap":34369548},{"date":"2022-04-08","current":-1.028722,"twenty":-25.433833,"median":-18.096089,"eighty":-11.254885,"marketCap":25084227},{"date":"2022-04-14","current":-1.023038,"twenty":-24.992465,"median":-17.985748,"eighty":-10.416286,"marketCap":24945640},{"date":"2022-04-22","current":-0.818431,"twenty":-24.264208,"median":-17.765064,"eighty":-1.459534,"marketCap":19956512},{"date":"2022-04-29","current":-0.785819,"twenty":-24.109729,"median":-17.047841,"eighty":-1.310625,"marketCap":19161305},{"date":"2022-05-06","current":-0.848456,"twenty":-23.491814,"median":-15.778907,"eighty":-1.093514,"marketCap":20688655},{"date":"2022-05-13","current":-0.733622,"twenty":-23.293198,"median":-15.03674,"eighty":-0.9878,"marketCap":18119930},{"date":"2022-05-20","current":-1.191784,"twenty":-22.840796,"median":-13.351383,"eighty":-0.962793,"marketCap":29436208},{"date":"2022-05-27","current":-1.506595,"twenty":-22.465633,"median":-12.854844,"eighty":-0.975297,"marketCap":37211810},{"date":"2022-06-03","current":-1.394163,"twenty":-22.30012,"median":-12.247963,"eighty":-0.98098,"marketCap":34434809},{"date":"2022-06-10","current":-1.366055,"twenty":-22.16771,"median":-11.696253,"eighty":-0.986663,"marketCap":33740559},{"date":"2022-06-17","current":-1.366055,"twenty":-22.09047,"median":-11.254885,"eighty":-1.009398,"marketCap":33740559},{"date":"2022-06-24","current":-1.197406,"twenty":-22.046334,"median":-10.482491,"eighty":-1.025312,"marketCap":29575058},{"date":"2022-07-01","current":-1.461622,"twenty":-21.902889,"median":-10.344563,"eighty":-1.033234,"marketCap":36101010},{"date":"2022-07-08","current":-1.506595,"twenty":-21.737376,"median":-5.965715,"eighty":-1.047976,"marketCap":37211810},{"date":"2022-07-15","current":-1.534704,"twenty":-21.682205,"median":-1.669623,"eighty":-1.083284,"marketCap":37906060},{"date":"2022-07-22","current":-1.377298,"twenty":-21.461521,"median":-1.540325,"eighty":-1.107154,"marketCap":34018259},{"date":"2022-07-29","current":-1.371676,"twenty":-21.428418,"median":-1.529082,"eighty":-1.149213,"marketCap":33879409},{"date":"2022-08-05","current":-1.414851,"twenty":-21.086358,"median":-1.509406,"eighty":-1.161365,"marketCap":34945778},{"date":"2022-08-12","current":-1.308074,"twenty":-20.181554,"median":-1.484109,"eighty":-1.191784,"marketCap":34079789},{"date":"2022-08-19","current":-1.073155,"twenty":-19.88363,"median":-1.475262,"eighty":-1.182306,"marketCap":27959337},{"date":"2022-08-26","current":-1.09985,"twenty":-19.729152,"median":-1.461622,"eighty":-1.149213,"marketCap":28654843},{"date":"2022-09-02","current":-1.035781,"twenty":-19.629844,"median":-1.425082,"eighty":-1.094994,"marketCap":26985628},{"date":"2022-09-09","current":-0.961034,"twenty":-19.585706,"median":-1.416649,"eighty":-1.051798,"marketCap":25038212},{"date":"2022-09-16","current":-0.977051,"twenty":-19.19951,"median":-1.413839,"eighty":-1.023038,"marketCap":25455515},{"date":"2022-09-23","current":-0.787514,"twenty":-18.316774,"median":-1.407462,"eighty":-0.983253,"marketCap":20517424},{"date":"2022-09-30","current":-0.726114,"twenty":-18.096089,"median":-1.388541,"eighty":-0.966203,"marketCap":18917760},{"date":"2022-10-07","current":-0.69408,"twenty":-17.985748,"median":-1.380109,"eighty":-0.928999,"marketCap":18083153},{"date":"2022-10-14","current":-0.646028,"twenty":-17.985748,"median":-1.371676,"eighty":-0.916325,"marketCap":16831242},{"date":"2022-10-21","current":-0.630011,"twenty":-17.930577,"median":-1.366055,"eighty":-0.871234,"marketCap":16413939},{"date":"2022-10-28","current":-0.573951,"twenty":-17.875406,"median":-1.366055,"eighty":-0.854252,"marketCap":14953376},{"date":"2022-11-04","current":-0.485856,"twenty":-17.654721,"median":-1.352001,"eighty":-0.819985,"marketCap":12658207},{"date":"2022-11-11","current":-0.448265,"twenty":-17.213353,"median":-1.343568,"eighty":-0.800862,"marketCap":12186169},{"date":"2022-11-18","current":-0.665994,"twenty":-17.047841,"median":-1.333979,"eighty":-0.785819,"marketCap":18105187},{"date":"2022-11-25","current":-0.686486,"twenty":-16.562335,"median":-1.321082,"eighty":-0.77203,"marketCap":18662269},{"date":"2022-12-02","current":-0.588739,"twenty":-16.308549,"median":-1.309839,"eighty":-0.750858,"marketCap":16004985},{"date":"2022-12-09","current":-0.712102,"twenty":-15.480984,"median":-1.267676,"eighty":-0.736159,"marketCap":19358623},{"date":"2022-12-16","current":-0.968253,"twenty":-15.085866,"median":-1.244005,"eighty":-0.741064,"marketCap":26322156},{"date":"2022-12-23","current":-1.111698,"twenty":-15.03674,"median":-1.214271,"eighty":-0.746567,"marketCap":30221735},{"date":"2022-12-30","current":-1.173175,"twenty":-14.853091,"median":-1.211283,"eighty":-0.747676,"marketCap":31892983},{"date":"2023-01-06","current":-1.19879,"twenty":-14.201016,"median":-1.209622,"eighty":-0.747791,"marketCap":32589336},{"date":"2023-01-13","current":-1.127067,"twenty":-13.362417,"median":-1.203028,"eighty":-0.749439,"marketCap":30639547},{"date":"2023-01-20","current":-1.101452,"twenty":-13.285178,"median":-1.197406,"eighty":-0.751884,"marketCap":29943194},{"date":"2023-01-27","current":-1.229528,"twenty":-13.163802,"median":-1.200909,"eighty":-0.753717,"marketCap":33424960},{"date":"2023-02-03","current":-1.608632,"twenty":-12.744502,"median":-1.208649,"eighty":-0.758575,"marketCap":43730990},{"date":"2023-02-10","current":-1.357604,"twenty":-12.2921,"median":-1.211283,"eighty":-0.764481,"marketCap":36906727},{"date":"2023-02-17","current":-1.173175,"twenty":-12.148655,"median":-1.210595,"eighty":-0.769597,"marketCap":31892983},{"date":"2023-02-24","current":-1.101452,"twenty":-11.751424,"median":-1.203913,"eighty":-0.774166,"marketCap":29943194},{"date":"2023-03-03","current":-1.075837,"twenty":-11.751424,"median":-1.198098,"eighty":-0.77443,"marketCap":29246840},{"date":"2023-03-10","current":-0.922146,"twenty":-11.641082,"median":-1.191784,"eighty":-0.785819,"marketCap":25068720},{"date":"2023-03-17","current":-0.932392,"twenty":-11.365227,"median":-1.185983,"eighty":-0.785819,"marketCap":25347261},{"date":"2023-03-24","current":-0.935614,"twenty":-11.254885,"median":-1.179936,"eighty":-0.787514,"marketCap":25434844},{"date":"2023-03-31","current":-3.073723,"twenty":-10.915583,"median":-1.185983,"eighty":-0.791513,"marketCap":25295856},{"date":"2023-04-06","current":-2.938614,"twenty":-10.569109,"median":-1.191784,"eighty":-0.796068,"marketCap":24183950},{"date":"2023-04-14","current":-2.98928,"twenty":-10.438354,"median":-1.197406,"eighty":-0.800131,"marketCap":24600914},{"date":"2023-04-21","current":-3.175054,"twenty":-10.383183,"median":-1.20347,"eighty":-0.807049,"marketCap":26129785},{"date":"2023-04-28","current":-3.884375,"twenty":-10.328012,"median":-1.210595,"eighty":-0.808596,"marketCap":31967290},{"date":"2023-05-05","current":-4.576322,"twenty":-10.272841,"median":-1.214215,"eighty":-0.816464,"marketCap":37661819},{"date":"2023-05-11","current":-3.813602,"twenty":-7.053908,"median":-1.216776,"eighty":-0.819363,"marketCap":31384849},{"date":"2023-05-19","current":-2.841134,"twenty":-4.874631,"median":-1.234651,"eighty":-0.836103,"marketCap":26642250},{"date":"2023-05-26","current":-2.380008,"twenty":-4.766155,"median":-1.244451,"eighty":-0.847813,"marketCap":22318115},{"date":"2023-06-02","current":-3.190234,"twenty":-4.657679,"median":-1.251483,"eighty":-0.848456,"marketCap":29915874},{"date":"2023-06-09","current":-3.254359,"twenty":-4.562763,"median":-1.270512,"eighty":-0.850774,"marketCap":30517199},{"date":"2023-06-16","current":-3.783393,"twenty":-4.400049,"median":-1.307224,"eighty":-0.856388,"marketCap":35478123},{"date":"2023-06-23","current":-4.10402,"twenty":-4.223113,"median":-1.309839,"eighty":-0.860781,"marketCap":38484743},{"date":"2023-06-30","current":-4.376552,"twenty":-4.23227,"median":-1.321082,"eighty":-0.865539,"marketCap":41040371},{"date":"2023-07-07","current":-4.152114,"twenty":-4.486677,"median":-1.332157,"eighty":-0.869324,"marketCap":38935736},{"date":"2023-07-14","current":-3.735299,"twenty":-4.39579,"median":-1.337947,"eighty":-0.871041,"marketCap":35027129},{"date":"2023-07-21","current":-3.572376,"twenty":-4.261126,"median":-1.345284,"eighty":-0.89609,"marketCap":33499345},{"date":"2023-07-28","current":-3.503009,"twenty":-4.195644,"median":-1.34919,"eighty":-0.905882,"marketCap":32848872},{"date":"2023-08-04","current":-3.503009,"twenty":-4.184638,"median":-1.356208,"eighty":-0.90747,"marketCap":32848872},{"date":"2023-08-11","current":-3.29491,"twenty":-4.158526,"median":-1.366055,"eighty":-0.911914,"marketCap":30897454},{"date":"2023-08-18","current":-2.330617,"twenty":-4.113639,"median":-1.367895,"eighty":-0.915656,"marketCap":26547513},{"date":"2023-08-25","current":-2.916846,"twenty":-4.034399,"median":-1.377298,"eighty":-0.920982,"marketCap":33225108},{"date":"2023-09-01","current":-2.902547,"twenty":-3.980385,"median":-1.38292,"eighty":-0.922146,"marketCap":33062240},{"date":"2023-09-08","current":-3.560267,"twenty":-3.968181,"median":-1.391352,"eighty":-0.923054,"marketCap":40554176},{"date":"2023-09-15","current":-3.631759,"twenty":-3.972707,"median":-1.409519,"eighty":-0.92366,"marketCap":41368517},{"date":"2023-09-22","current":-4.932901,"twenty":-4.034479,"median":-1.414345,"eighty":-0.926863,"marketCap":56189522},{"date":"2023-09-29","current":-6.358344,"twenty":-4.1851,"median":-1.416649,"eighty":-0.928999,"marketCap":72426414},{"date":"2023-10-06","current":-6.479291,"twenty":-4.315729,"median":-1.429506,"eighty":-0.931035,"marketCap":73804091},{"date":"2023-10-13","current":-5.615385,"twenty":-4.616006,"median":-1.461622,"eighty":-0.934325,"marketCap":63963545},{"date":"2023-10-20","current":-4.872427,"twenty":-4.777335,"median":-1.471175,"eighty":-0.943737,"marketCap":55500676},{"date":"2023-10-27","current":-6.375622,"twenty":-4.847512,"median":-1.475262,"eighty":-0.949152,"marketCap":72623225},{"date":"2023-11-03","current":-6.064616,"twenty":-4.932901,"median":-1.484109,"eighty":-0.950356,"marketCap":69080629},{"date":"2023-11-10","current":-6.410178,"twenty":-5.131598,"median":-1.509406,"eighty":-0.958007,"marketCap":73016847},{"date":"2023-11-17","current":-6.195423,"twenty":-5.719054,"median":-1.529082,"eighty":-0.961034,"marketCap":87580854},{"date":"2023-11-24","current":-6.703742,"twenty":-5.892712,"median":-1.540325,"eighty":-0.965169,"marketCap":94766658},{"date":"2023-12-01","current":-7.181577,"twenty":-6.076855,"median":-1.603509,"eighty":-0.967843,"marketCap":101521514},{"date":"2023-12-08","current":-7.01293,"twenty":-6.195898,"median":-1.669623,"eighty":-0.968253,"marketCap":99137447},{"date":"2023-12-15","current":-7.982654,"twenty":-6.218411,"median":-2.022607,"eighty":-0.97102,"marketCap":112845832},{"date":"2023-12-22","current":-10.034533,"twenty":-6.379078,"median":-2.409758,"eighty":-0.973043,"marketCap":141851979},{"date":"2023-12-29","current":-9.430212,"twenty":-6.451646,"median":-2.432071,"eighty":-0.974846,"marketCap":133309073},{"date":"2024-01-05","current":-8.50265,"twenty":-6.565681,"median":-2.473599,"eighty":-0.977051,"marketCap":120196705},{"date":"2024-01-12","current":-8.685352,"twenty":-6.703742,"median":-2.585988,"eighty":-0.97757,"marketCap":122779444},{"date":"2024-01-19","current":-7.518873,"twenty":-6.911741,"median":-2.60785,"eighty":-0.978313,"marketCap":106289648},{"date":"2024-01-26","current":-5.256184,"twenty":-7.018552,"median":-2.655395,"eighty":-0.982302,"marketCap":74303417},{"date":"2024-02-02","current":-5.466993,"twenty":-6.911741,"median":-2.795833,"eighty":-0.986834,"marketCap":77283501},{"date":"2024-02-09","current":-5.804128,"twenty":-6.774012,"median":-2.816758,"eighty":-0.987729,"marketCap":82049361},{"date":"2024-02-16","current":-5.229106,"twenty":-6.712174,"median":-2.843244,"eighty":-0.988695,"marketCap":73920631},{"date":"2024-02-23","current":-5.498647,"twenty":-6.703742,"median":-2.873951,"eighty":-0.994969,"marketCap":77730973},{"date":"2024-03-01","current":-6.019761,"twenty":-6.693474,"median":-2.904837,"eighty":-1.003911,"marketCap":85097634},{"date":"2024-03-08","current":-6.073669,"twenty":-6.663866,"median":-2.910842,"eighty":-1.008419,"marketCap":85859703},{"date":"2024-03-15","current":-5.10332,"twenty":-6.640353,"median":-2.938614,"eighty":-1.009238,"marketCap":72142472},{"date":"2024-03-22","current":-5.462708,"twenty":-6.634794,"median":-2.972392,"eighty":-1.015386,"marketCap":77222928},{"date":"2024-03-28","current":-5.516617,"twenty":-6.623022,"median":-3.014613,"eighty":-1.020906,"marketCap":77984996},{"date":"2024-04-05","current":-4.808357,"twenty":-6.594122,"median":-3.042817,"eighty":-1.023666,"marketCap":74173940},{"date":"2024-04-12","current":-4.945249,"twenty":-6.572627,"median":-3.073723,"eighty":-1.026253,"marketCap":76285653},{"date":"2024-04-19","current":-3.781661,"twenty":-6.536582,"median":-3.124388,"eighty":-1.031174,"marketCap":58336088},{"date":"2024-04-26","current":-3.593434,"twenty":-6.487476,"median":-3.158168,"eighty":-1.035224,"marketCap":55432482},{"date":"2024-05-03","current":-3.953922,"twenty":-6.475173,"median":-3.175054,"eighty":-1.037469,"marketCap":60993385},{"date":"2024-05-10","current":-3.731407,"twenty":-6.445469,"median":-3.190234,"eighty":-1.04472,"marketCap":57560857},{"date":"2024-05-17","current":-3.263275,"twenty":-6.403267,"median":-3.190234,"eighty":-1.053237,"marketCap":59409141},{"date":"2024-05-24","current":-3.07473,"twenty":-6.385989,"median":-3.190496,"eighty":-1.057425,"marketCap":55976613},{"date":"2024-05-31","current":-3.03122,"twenty":-6.372166,"median":-3.190496,"eighty":-1.060468,"marketCap":55184491},{"date":"2024-06-07","current":-2.988868,"twenty":-6.351433,"median":-3.175054,"eighty":-1.060468,"marketCap":54413458},{"date":"2024-06-14","current":-3.017886,"twenty":-6.323788,"median":-3.168385,"eighty":-1.060468,"marketCap":54941744},{"date":"2024-06-21","current":-2.785741,"twenty":-6.296199,"median":-3.161751,"eighty":-1.064566,"marketCap":50715456},{"date":"2024-06-28","current":-3.090431,"twenty":-6.282377,"median":-3.158171,"eighty":-1.065591,"marketCap":56262459},{"date":"2024-07-05","current":-3.554721,"twenty":-6.254675,"median":-3.158171,"eighty":-1.065591,"marketCap":64715035},{"date":"2024-07-12","current":-2.916322,"twenty":-6.209345,"median":-3.158168,"eighty":-1.070714,"marketCap":53092743},{"date":"2024-07-15","current":-3.061413,"twenty":-6.207036,"median":-3.158166,"eighty":-1.071202,"marketCap":55734173},{"date":"2024-08-02","current":-3.017886,"twenty":-6.204727,"median":-3.149722,"eighty":-1.07169,"marketCap":54941744},{"date":"2024-08-09","current":-2.901813,"twenty":-6.196849,"median":-3.133958,"eighty":-1.074228,"marketCap":52828600},{"date":"2024-08-16","current":-2.727429,"twenty":-6.184568,"median":-3.121919,"eighty":-1.075837,"marketCap":51881405},{"date":"2024-08-23","current":-3.189215,"twenty":-6.151983,"median":-3.124388,"eighty":-1.077452,"marketCap":60665558},{"date":"2024-08-30","current":-3.059338,"twenty":-6.126842,"median":-3.121919,"eighty":-1.082358,"marketCap":58195015},{"date":"2024-09-06","current":-3.030476,"twenty":-6.115383,"median":-3.11765,"eighty":-1.08762,"marketCap":57646005},{"date":"2024-09-13","current":-2.616311,"twenty":-6.073669,"median":-3.10494,"eighty":-1.093836,"marketCap":49767718},{"date":"2024-09-20","current":-2.554258,"twenty":-6.071858,"median":-3.096621,"eighty":-1.094187,"marketCap":48587347},{"date":"2024-09-27","current":-2.294503,"twenty":-6.055645,"median":-3.0882,"eighty":-1.094875,"marketCap":43646261},{"date":"2024-10-04","current":-1.933732,"twenty":-6.018828,"median":-3.074226,"eighty":-1.096448,"marketCap":36783641},{"date":"2024-10-11","current":-1.991456,"twenty":-6.007724,"median":-3.06426,"eighty":-1.097509,"marketCap":37881661},{"date":"2024-10-18","current":-2.438812,"twenty":-5.972157,"median":-3.060376,"eighty":-1.10017,"marketCap":46391309},{"date":"2024-10-25","current":-2.294503,"twenty":-5.941702,"median":-3.03122,"eighty":-1.101452,"marketCap":43646261},{"date":"2024-10-31","current":-2.381088,"twenty":-5.916977,"median":-3.023057,"eighty":-1.101452,"marketCap":45293290},{"date":"2024-11-08","current":-2.525397,"twenty":-5.911944,"median":-3.017886,"eighty":-1.101452,"marketCap":48038338},{"date":"2024-11-15","current":-2.035664,"twenty":-5.909113,"median":-3.016045,"eighty":-1.101452,"marketCap":44562371},{"date":"2024-11-22","current":-2.111059,"twenty":-5.888612,"median":-2.996328,"eighty":-1.106575,"marketCap":46212830},{"date":"2024-11-29","current":-2.65139,"twenty":-5.866126,"median":-2.988868,"eighty":-1.110673,"marketCap":58041114},{"date":"2024-12-06","current":-3.166589,"twenty":-5.85853,"median":-2.974359,"eighty":-1.111698,"marketCap":69319245},{"date":"2024-12-13","current":-2.676521,"twenty":-5.85743,"median":-2.967105,"eighty":-1.123993,"marketCap":58591266},{"date":"2024-12-20","current":-2.789614,"twenty":-5.829133,"median":-2.955503,"eighty":-1.127067,"marketCap":61066954},{"date":"2024-12-27","current":-2.638824,"twenty":-5.811316,"median":-2.943891,"eighty":-1.127067,"marketCap":57766037},{"date":"2025-01-03","current":-2.764482,"twenty":-5.804128,"median":-2.938614,"eighty":-1.127067,"marketCap":60516801},{"date":"2025-01-10","current":-2.827311,"twenty":-5.790569,"median":-2.938614,"eighty":-1.129098,"marketCap":61892183},{"date":"2025-01-17","current":-2.588561,"twenty":-5.735516,"median":-2.916584,"eighty":-1.137241,"marketCap":56665732},{"date":"2025-01-24","current":-2.575995,"twenty":-5.73225,"median":-2.915797,"eighty":-1.137313,"marketCap":56390655},{"date":"2025-01-31","current":-2.475468,"twenty":-5.73225,"median":-2.904837,"eighty":-1.137313,"marketCap":54190044},{"date":"2025-02-07","current":-2.538297,"twenty":-5.719054,"median":-2.903771,"eighty":-1.147559,"marketCap":55565426},{"date":"2025-02-14","current":-2.5006,"twenty":-5.615385,"median":-2.901813,"eighty":-1.148076,"marketCap":54740197},{"date":"2025-02-21","current":-2.236717,"twenty":-5.579497,"median":-2.888249,"eighty":-1.152623,"marketCap":48963593},{"date":"2025-02-28","current":-1.985401,"twenty":-5.541774,"median":-2.868902,"eighty":-1.165176,"marketCap":43462066},{"date":"2025-03-07","current":-2.073362,"twenty":-5.534586,"median":-2.845354,"eighty":-1.172146,"marketCap":45387601},{"date":"2025-03-14","current":-1.985401,"twenty":-5.520211,"median":-2.842004,"eighty":-1.173175,"marketCap":43462066},{"date":"2025-03-21","current":-2.286981,"twenty":-5.502241,"median":-2.829268,"eighty":-1.174313,"marketCap":50063899},{"date":"2025-03-28","current":-2.193309,"twenty":-5.498647,"median":-2.816758,"eighty":-1.178868,"marketCap":47404804},{"date":"2025-04-04","current":-2.026566,"twenty":-5.473324,"median":-2.814746,"eighty":-1.182724,"marketCap":43800930},{"date":"2025-04-11","current":-1.876497,"twenty":-5.463565,"median":-2.796559,"eighty":-1.183421,"marketCap":40557444},{"date":"2025-04-17","current":-2.01374,"twenty":-5.462708,"median":-2.786951,"eighty":-1.186495,"marketCap":43523709},{"date":"2025-04-24","current":-2.193309,"twenty":-5.45552,"median":-2.764482,"eighty":-1.18984,"marketCap":47404804}],"updateTime":1745655966988}}}